Download now: Oil Price Outlook 2024

A Surprising Winner From the COVID-19 Fallout

Keith Kohl

Written By Keith Kohl

Posted October 28, 2020

Day 225 of COVID.

It’s been nearly eight full months since our governor here in Maryland issued orders for bars, restaurants, movie theaters, and gyms across the state to close up shop.

That was on March 16.

To date, there have been roughly 8.7 million COVID-19 cases in the United States and a death toll of 225,084 that will inevitably tick higher for the foreseeable future.

Globally, over 44 million COVID cases have been counted.

We both know the numbers don’t look good. Could they have been worse? Could they have been better?

As my colleague Jeff Siegel told me earlier, “Let the bullshit media sort it out — we’re focused on something far more important than the political football of blame being tossed back and forth in Washington.”

I knew where he was going with that line of thinking.

You see, Jeff has been one of the rare investors who can spot a trend years ahead of the investment herd.

He was teaching me about the most lucrative solar stocks a decade ago.

And I knew right away that he struck pay dirt again.

I just didn’t realize how the rest of us missed it for so long.

Fortunately, he’s going to help us.

The COVID Consequences

If health care isn’t the single greatest concern on every American’s mind these days, it certainly will be as we head into the winter months.

In the last week, 29 states have reported a record number of infections.

Call it the second, third, or fourth wave… It doesn’t matter.

And it’s getting harder to find optimistic people out there.

Yet amidst the clamor over wearing masks, social distancing, and more schools switching back to remote learning, there’s an even larger issue hanging above our heads in this pandemic life to which we’ve transitioned.

When Jeff told me that mental illness has been the elephant in the room everyone is ignoring in this pandemic, he was spot-on.

The devastation COVID-19 has had on our economy alone doesn’t come without consequences. I’ve even seen some polls show that more than half of U.S. adults have reported their mental health has been negatively impacted over stress from the coronavirus.

In fact, health professionals are now expecting a surge in patients with PTSD.

Think about it…

The widespread lockdowns that occurred also came with dire consequences. Extreme isolation, job loss, and substance abuse are just a few of the outcomes we’ve experienced during this pandemic.

The question now is how to help, and that’s where Jeff’s research will pay off in spades for his readers.

When I told you health care was arguably the greatest issue on Americans’ minds, I didn’t really give you the whole picture.

You see, it’s not just our everyday routine that is changing.

In the medical community, new treatments to improve the quality of life for patients are researched every day.

Of course, there are also new treatments that have been constantly developing over years, even decades.

And all we need sometimes is that one key to unlock the door.

That’s when Jeff mentioned the little-known breakthrough that scientists have taken to calling Molecule 520.

Never heard of it?

Believe me, neither had I before this morning.

What sets it apart from current treatments that deal with the mental issues plaguing our pandemic society is that for the first time, the U.S. government won’t be able to ignore the overwhelmingly strong data coming out now.

One peer-reviewed study even concluded that this new treatment would save more than $103 million in healthcare costs.

Now the FDA is starting to lend Molecule 520 its support, and Jeff believes there’s still a tiny window of opportunity left for investors like us.

His latest investment report is a must-read, and as a premium member of Energy and Capital, you have exclusive access to his report.

You can find the full details right here.

I suggest you take a few minutes out of your day and check it out for yourself.

Until next time,

Keith Kohl Signature

Keith Kohl

follow basicCheck us out on YouTube!

A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.

For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.

Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.

Angel Pub Investor Club Discord - Chat Now

Keith Kohl Premium

Introductory

Advanced

Hydrogen Fuel Cells: The Downfall of Tesla?

Lithium has been the front-runner in the battery technology market for years, but that is all coming to an end. Elon Musk is against them, but Jeff Bezos is investing heavily in them. Hydrogen Fuel Cells will turn the battery market upside down and we've discovered a tiny company that is going to make it happen...

Sign up to receive your free report. After signing up, you'll begin receiving the Energy and Capital e-letter daily.